A new drug for penile cancer after first treatment stops working
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called sacituzumab tirumotecan for penile cancer that has spread or cannot be cured with surgery or radiation. It is for people whose cancer got worse after standard chemotherapy. The drug is given as an infusion and may help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have penile cancer that has spread or cannot be removed with surgery.
- Your cancer got worse during or within 12 months after finishing platinum-based chemotherapy (like cisplatin or carboplatin).
- You have at least one tumor that can be measured on a scan.
- You are at least 18 years old.
- You are in generally good health (able to do light activity) and have adequate organ function.
- You are willing to provide a tumor tissue sample from a previous biopsy or surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a new drug called Sac-TMT for people with advanced squamous cell carcinoma of the vagina or vulva that has spread or cannot be cured with standard treatments. The drug targets a protein on cancer cells to deliver chemotherapy directly to the tumor, potentially slowing or stopping its growth.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new medication, sacituzumab tirumotecan, for people with anal or rectal cancer that has spread or cannot be removed and has not responded to previous treatments. The drug is designed to target and kill cancer cells.
This trial tests a new drug for pancreatic cancer that has spread or come back after at least one prior treatment. The drug targets a protein on cancer cells to help stop tumor growth.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
Hear when a new Penile Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.